2. Search Result
Search Result
Results for "

Gonadotropin releasing hormone receptor

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

8

Peptides

1

Recombinant Proteins

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0009A
    Cetrorelix Acetate
    1 Publications Verification

    SB-75 acetate

    		 GnRH Receptor Neurological Disease Endocrinology
    Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM .
    Cetrorelix Acetate
  • HY-W041308
    DCOIT

    Kathon 930

    		 GnRH Receptor Endocrinology
    DCOIT is a representative isothiazolinone that stimulates the gonadotropin-releasing hormone receptor (GnRHR)-mediated synthesis of follicle-stimulating hormone and luteinizing hormone in the brain. DCOIT interferes with G protein-coupled receptors, MAPK and Ca 2+ signaling cascades .
    DCOIT
  • HY-P1428
    RFRP-1(human)

    		Neuropeptide Y Receptor Endocrinology
    RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits gonadotropin. RFRP-1(human) is a potent Neuropeptide FF (NPFF) receptor agonist with EC50s of 0.0011 nM and 29 nM for NPFF2 and NPFF1, respectively .
    RFRP-1(human)
  • HY-U00289
    Opigolix

    ASP-1707

    		 GnRH Receptor Inflammation/Immunology Endocrinology
    Opigolix (ASP-1707) is a Gonadotropin-releasing hormone (GnRH) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.
    Opigolix
  • HY-P0009B
    Cetrorelix diacetate

    SB-75 diacetate

    		 GnRH Receptor Neurological Disease Endocrinology
    Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM .
    Cetrorelix diacetate
  • HY-120767
    Linzagolix choline

    KLH-2109 choline; OBE-2109 choline

    		 GnRH Receptor Inflammation/Immunology Cancer
    Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .
    Linzagolix choline
  • HY-16168B
    Degarelix acetate hydrate

    FE 200486 acetate hydrate

    		 GnRH Receptor Apoptosis Endocrinology Cancer
    Degarelix acetate hydrate (FE 200486 acetate hydrate) is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research .
    Degarelix acetate hydrate
  • HY-133080
    BAY-784

    		GnRH Receptor Cancer
    BAY-784 is a gonadotropin releasing hormone receptor (GnRH-R) antagonist probe with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively .
    BAY-784
  • HY-16168AS
    Degarelix-d7

    FE 200486-d7 free base

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Degarelix-d7 (FE 200486-d7 free base) is deuterium labeled Degarelix. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.
    Degarelix-d7
  • HY-16168
    Degarelix acetate

    FE 200486

    		 GnRH Receptor Cancer
    Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC50 = 3 nM). Degarelix acetate (FE 200486) is used for the research of prostate cancer .
    Degarelix acetate
  • HY-16168A
    Degarelix
    Maximum Cited Publications
    8 Publications Verification

    FE 200486 free base

    		 GnRH Receptor Apoptosis Endocrinology Cancer
    Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC50 = 3 nM). Degarelix acetate Degarelix acetate (FE 200486) is used for the research of prostate cancer .
    Degarelix
  • HY-16168AR
    Degarelix (Standard)

    		GnRH Receptor Apoptosis Endocrinology Cancer
    Degarelix (Standard) is the analytical standard of Degarelix. This product is intended for research and analytical applications. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research .
    Degarelix (Standard)
  • HY-14789
    (R)-Elagolix

    NBI-56418

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Endocrinology Cancer
    Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    (R)-Elagolix
  • HY-14369
    Elagolix sodium

    NBI-56418 sodium

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Endocrinology Cancer
    Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix sodium
  • HY-109532
    Ganirelix acetate

    Ganirest

    		 GnRH Receptor Metabolic Disease
    Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS) .
    Ganirelix acetate
  • HY-P3317
    Azaline

    Azaline A

    		 GnRH Receptor Endocrinology
    Azaline (Azaline A) is a gonadotropin-releasing hormone (GnRH) receptor antagonist with a KD value of 0.48 nM. Azaline can effectively induce histamine release, with an effect comparable to that of GnRH, and it can completely inhibit ovulation at a dose of 2.0-3.0 μg per female rat. Azaline has potential applications in regulating reproductive functions .
    Azaline
  • HY-144863
    BAY 1214784

    		GnRH Receptor Cancer
    BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids .
    BAY 1214784
  • HY-P3862
    [MePhe7]-Neurokinin B

    		Neurokinin Receptor Neurological Disease Endocrinology
    [MePhe7]-Neurokinin B is an neurokinin NK-3 receptor (NK3R) agonist with an IC50 value of 3 nM. [MePhe7]-Neurokinin B is a potential regulator of pulsatile gonadotropin-releasing hormone (GnRH) secretion via activation of the neurokinin-3 receptor (NK3R) .
    [MePhe7]-Neurokinin B
  • HY-16474
    Relugolix

    TAK-385

    		 GnRH Receptor Endocrinology Cancer
    Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix
  • HY-16474S
    Relugolix-d6

    TAK-385-d6

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Relugolix-d6 is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].
    Relugolix-d6
  • HY-16474R
    Relugolix (Standard)

    		GnRH Receptor Endocrinology Cancer
    Relugolix (Standard) is the analytical standard of Relugolix. This product is intended for research and analytical applications. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: